In the study, 1,844 women were enrolled and mother and infant pairs randomized to three arms: single 200 mg nevirapine dose to the mother in labor and 6 mg to the baby within 72 hours of birth (the nevirapine-nevirapine arm); nevirapine dose to the mother and placebo to the infant (nevirapine-placebo) and both mother and baby receiving placebo (placebo-placebo). Additionally all mothers received zidovudine from 28 weeks of gestation and infants one week of zidovudine and formula feeding. The study endpoint was HIV infection of the infant.
Presenting author Marc Lallemant reported that the placebo-placebo arm was discontinued following the trial's first interim analysis due to the highly significant 80% reduction in transmission among those receiving the additional drug: 1.1% in the nevirapine-nevirapine arm and 6.3% in the placebo-placebo arm (p=0.00026). Subsequent analysis showed that transmission rates between the nevirapine-nevirapine and the nevirapine-placebo arms did not differ dramatically: 2.0% and 2.8%, respectively.
In a comment from the floor after this presentation, John Mellors remarked that these findings echoed those from ACTG 398, in which patients receiving efavirenz-containing regimens had responded less well if previously exposed to an NNRTI, even without detectable resistance.3 These reports suggest that prior NNRTI exposure can select minor resistant variants not detectable by standard genotype assays, but which can nevertheless contribute to the failure of subsequent NNRTI-containing regimens.
At six weeks following the nevirapine prophylaxis, 12/30 (40%) of women and 40% of infants had detectable resistance. The K103N mutation was the most common mutation in 10/12 (83%) of the mothers. Other mutations reported in the mothers included: Y181C in 3/12 (25%), Y188C in 3/12 (25%), V106M in 2/12 (17%) and G190A in 1/12 (8%) Two or more mutations were found in 4/12 (33.3%) mothers. Among the infants, the Y181N was the most common mutation and was present in 11/12 (92%) of the children (including one of the twins). Additionally 2/12 infants (17%) had the K103N and another 1/12 (8%) had a subtype C associated V106M mutation.
The investigators concluded: "Given the high rate of resistance in mothers and infants after single-dose nevirapine, the search for safer regimens to prevent MTCT should be intensified."
Baseline and four week samples were available for 63 women. The investigators reported 21/63 (33.3%) of women had developed nevirapine resistance at week four, with the K103N being the most common mutation. They also reported that mothers with infected and uninfected infants developed resistance at the same rate (33.3%), 7/21 and 14/42, respectively. No zidovudine resistance was detected in this group.
Analysis of nevirapine plasma concentrations revealed wide inter-patient variability with a median concentration of 648 (range 417-954) ng/mL. Resistance was significantly associated with a higher plasma concentration of nevirapine; among women who received two doses of nevirapine, 3/4 (75%) acquired resistance.
Additionally, 6/26 (23%) of the infected infants developed nevirapine resistance at four weeks post partum, and follow-up samples in two children -- one at 3 and one at 12 months old -- detected archived mutations.
The investigators note that the association between high nevirapine plasma concentrations and resistance suggests, "That a high level of nevirapine concentration induced a prolonged viral replication under suboptimal drug selective pressure which promotes the emergence of resistant strains." Concerning the infants they write: "Recent studies have reported a negative impact of nevirapine resistance on a subsequent treatment including nevirapine; our results raise anxiety for those very young children presenting with resistant viruses."
The investigators found a significantly higher overall rate of resistance (i.e., any nevirapine mutation) at 6-8 weeks than at 7 days, 47/140 (34%) and 31/140 (22%), respectively, in women with either A or D subtypes (p=0.013). There was a higher rate of accumulation of mutations for subtype D vs. A. The K103N mutation was detected at a higher rate in the 6-8 week samples: 41/140 (29%), than the 7 day samples: 18/140 (13%), (p=0.0001) across both subtypes. Conversely the detection rate for the Y181C mutation was higher at 7 days than at 6-8 weeks overall, 26/140 (19%) and 15/140 (11%), respectively (p=0.0145). The investigators added: "Furthermore, Y181 faded quickly in subtype A with little or no fading in subtype D."
The report suggests that nevirapine mutations are better tolerated by subtype D HIV than subtype A and that HIV-1 subtype should be considered in the design and interpretation of studies to determine whether single-dose nevirapine compromises subsequent NNRTI containing treatment.
Jourdain et al. showed dramatically reduced response in women receiving NNRTI containing regimens following acquisition of nevirapine resistance after receiving single-dose nevirapine to reduce MTCT (at six months 75% unexposed, 53% of exposed but with no detectable mutations and 34% of exposed with detectable resistance were below 50 copies). Additionally when Mellors, et al., evaluated the role of minor NNTRI mutations, failure to achieve viral suppression was associated with previous NNRTI experience and NNRTI mutations at baseline. Although genotyping failed to detect NNRTI mutations in 50/216 (23%) baseline samples in the NNRTI experienced patients, this group performed no better than those with detectable NNRTI resistance and much worse that the NNRTI-naive group who similarly showed no mutations.
Furthermore, as the Thai study demonstrated, adding nevirapine to background zidovudine is not associated with significantly less nevirapine resistance. The early emergence of the Y181C in HIVNET 012 may help to explain the different rates of NNRTI mutations seen in mothers compared to infants, as previously reported. The more rapid "fading" of the Y181C would seem to suggest that this mutation is "less fit" relative to both K103N and wild-type virus, at least in sub-type A virus. Better news is that no resistance was reported for zidovudine as prescribed in the DITRAME study.
These studies confirm the efficacy of nevirapine to contribute to the reduction mother-to-child transmission. But they also confirm the likelihood of rapidly selecting resistance mutations when less-than-suppressive concentrations of the drug are allowed to persist. The finding that single-dose nevirapine exposure can negatively impact future outcomes to such a dramatic extent should lead to a rapid change in policy, especially in countries rolling out combination therapy. The potential benefit of nevirapine or efavirenz as part of a subsequent regimen for the mother must be protected, and the use of nevirapine for prevention of mother-to-child transmission (PMTCT) of HIV restricted to effective combinations only and with due consideration for its prolonged clearance from the body, which varies considerably between individuals.
Polly Clayden is with HIV i-Base. This article originally appeared in: HIV Treatment Bulletin, Volume 3 and Volume 5. www.i-base.org.uk.
|What Is to Be Done?|
Adding Combivir to Single-Dose Nevirapine for PMTCT Significantly Reduces Resistance
At the World AIDS Conference in Bangkok, James McIntyre from the University of Witwatersrand, Johannesburg, South Africa, presented an interim analysis from the currently ongoing TOPS (Treatment Options Preservation Study).1
The study was originally planned to enroll 300 treatment-naive women and their infants and randomizes mothers and babies to one of three arms. Arm 1 involves single-dose nevirapine given to mothers at onset of labor and single-dose to the baby. Arm 2 involves single-dose nevirapine to mother and baby plus 4 days twice-daily Combivir (zidovudine/lamivudine combined pill) to mother and baby starting during labor and within 24-72 hours of birth, respectively. Arm 3 involves single-dose nevirapine to mother and baby plus 7 days twice-daily Combivir. Enrollment and informed consent is at 34 weeks and women are randomized in labor.
The objective is to determine whether adding either 4 or 7 days Combivir can reduce the occurrence of nevirapine resistance in treatment-naive HIV-positive pregnant women, which would in turn preserve their future treatment options.
At the time of this interim analysis 156 women had entered the trial and six week resistance data was available for 61 (18, 20, 23 mothers in the single-dose nevirapine, single-dose nevirapine plus 4 days Combivir and single-dose nevirapine plus 7 days Combivir arms, respectively).
The investigators reported that at 2 weeks, 57.1% of the mothers receiving single-dose nevirapine had detectable nevirapine resistance vs. 0% in either of the other two arms. At 6 weeks, resistance was detected in 53.3%, 5.00% and 13.6% of mothers receiving single-dose nevirapine, single-dose nevirapine plus 4 days Combivir and single-dose nevirapine plus 7 days Combivir, respectively. They noted that 9/18 (50%), 1/20 (5%) and 3/23 (13%) of mothers from the three groups had detectable resistance at any time after baseline. Overall, resistance was detected in 50% receiving single-dose nevirapine and in 9.3% of those receiving nevirapine plus Combivir (p=0.001). The most frequently detected mutations at any time were the K103N and the Y181C. There was no resistance to either zidovudine or lamivudine.
Following these dramatic results, enrollment into the single-dose nevirapine arm of the study was closed in June 2004. McIntyre explained: "The trial was originally powered expecting 20% resistance in the nevirapine arm but emerging data, notably Neil Martinson's Retrovirus report of 39%, suggest the real figure is much higher." The trial is continuing with adjusted sample size (150 mothers in each arm) to compare 4 and 7 days of Combivir as the optimal duration of this supplementation is uncertain.
Polly Clayden (HIV Treatment Bulletin, Volume 5, Number 7, Aug/Sep 2004.)